AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer

Clinical Colorectal Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles